<DOC>
	<DOCNO>NCT02107196</DOCNO>
	<brief_summary>Irritable Bowel Syndrome diarrhoea ( IBS-D ) functional gastrointestinal disorder characterise chronic recurrent abdominal pain discomfort diarrhoea . This trial aim evaluation efficacy safety oral ibodutant 10 mg daily compare placebo woman IBS-D 12-week treatment period .</brief_summary>
	<brief_title>12-Week Efficacy Safety Study Ibodutant Women With Irritable Bowel Syndrome With Diarrhea ( IBS-D )</brief_title>
	<detailed_description>The study evaluate efficacy safety ibodutant 10 mg , give daily 12 week comparison placebo female IBS-D patient . Randomisation ibodutant placebo 1:1 . Efficacy evaluate term weekly response abdominal pain intensity stool consistency 12 week treatment least 50 % week treatment . The clinical phase study comprise 2 week screen patient 's eligibility , 2-week run-in period ( treatment-free ) IBS severity assessment , 12-week double-blind treatment period , 4-week randomise withdrawal ( RW ) period 2-week safety follow-up , result maximum 22-week overall duration study patient . Patients report IBS-related symptom daily telephone-based electronic diary run-in end treatment .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>At screening : Female patient age 18 year old . Clinical diagnosis IBSD accord follow symptomsbased criterion per Rome III modular questionnaire criterion : 1 . Recurrent abdominal pain discomfort least 3 day per month last 3 month associate least 2 follow characteristic : ) improvement defecation ; b ) onset associate change frequency stool ; c ) onset associate change form ( appearance ) stool . 2 . Symptomonset least 6 month prior diagnosis . 3 . Loose watery stool least 25 % time last 3 month AND hard lumpy stool less 25 % time last 3 month . 4 . Additional criterion : 3 bowel movement per day least 25 % time last 3 month . For patient old 50 year OR patient positive family history colorectal cancer : normal result colonoscopy/flexible sigmoidoscopy perform within last 5 year . For patient age 65 year old : absence ischaemic colitis , microscopy colitis organic gastrointestinal disease evidence result colonoscopy/flexible sigmoidoscopy biopsy perform within 6 month . For woman childbearing potential : Use highly effective contraceptive method failure rate &lt; 1 % per year throughout entire study period . Physical examination without clinically relevant abnormality screen . No clinically relevant abnormality 12Lead ECG laboratory finding . Mentally competent , able give write informed consent , compliant undergo visit procedure . Unrestricted access touchtone telephone . Willingness refrain use loperamide within 3 day prior runin visit runin period . Additional criterion randomisation : During week runin period : 1 . A weekly average bad abdominal pain past 24 hour score ≥3.0 0 10 point scale . 2 . At least one bowel movement day . 3 . A weekly average least 3 bowel movement per day . 4 . At least one stool consistency Type 6 Type 7 accord Bristol Stool Scale ( BSS ) least 2 day per week . 5 . Less 2 bowel movement consistency Type 1 Type 2 accord BSS per week . Adequate compliance ediary recording procedure define least 11 14 day ( ≥75 % ) nominal daily data entry . Male gender . Diagnosis IBS subtype constipation , mixed IBS , unsubtyped IBS . Colonic major abdominal surgery , major abdominal surgery elective major surgery plan expect study . History organic GI abnormality , inflammatory bowel disease , complicate diverticulosis , ischaemic colitis , microscopic colitis . History pancreatitis , active biliary duct disease , cholecystitis symptomatic gallbladder stone disease previous 6 month . History gluten enteropathy lactose intolerance . Current previous diagnosis neoplasia . History endometriosis . History positive test ova parasite , clostridium difficile toxin occult blood stool previous 6 month . History human immunodeficiency virus infection . History major cardiovascular event previous 6 month . Uncontrolled hypertension , insulindependent diabetes mellitus abnormal thyroid function . Major psychiatric neurological disorder unstable medical condition may compromise efficacy safety assessment . Evidence clinically significant hepatic disease , severe renal insufficiency anemia . Relevant change dietary habit , lifestyle , exercise regimen previous 2 month . Use prohibit concurrent medication within previous month antibiotic , antimuscarinic drug , drug enhance GI motility analgesic . Pregnancy breastfeed . Inability understand collaborate throughout study . Participation clinical study previous 4 week concurrent enrollment clinical study . Any condition would compromise wellbeing patient .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Colon , irritable</keyword>
	<keyword>Bowel disease</keyword>
	<keyword>Diarrhea</keyword>
</DOC>